The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.
paper
Cited
Public
- Authors
- Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N; Kampman, Kyle M; Dackis, Charles A; Pettinati, Helen M; O'brien, Charles P; Oslin, David W; Lohoff, Falk W; Berrettini, Wade H
- Year
- 2014
- Journal
- Annals of human genetics
- PMID
- 24359476
- DOI
- 10.1111/ahg.12046
- PMCID
- PMC4013426
The risk for drug addiction is partially heritable. Genes of the dopamine system are likely candidates to harbour risk variants, as dopamine neurotransmission is involved in mediating the rewarding effects of drugs of abuse. One functional single nucleotide polymorphism in dopamine receptor D2 (DRD2), rs1076560, is involved in regulating splicing of the gene and alters the ratio of DRD2 isoforms located pre- and postsynaptically. rs1076560 has been previously associated with cocaine abuse and we set out to confirm this association in a sample of European American (EA) (n = 336) and African American (AA) (n = 1034) cocaine addicts and EA (n = 656) and AA (n = 668) controls. We also analysed the role of rs1076560 in opioid dependence by genotyping EA (n = 1041) and AA (n = 284) opioid addicts. rs1076560 was found to be nominally associated with opioid dependence in EAs (p = 0.02, OR = 1.27) and AAs (p = 0.03, OR = 1.43). When both opioid-addicted ancestral samples were combined, rs1076560 was significantly associated with increased risk for drug dependence (p = 0.0038, OR = 1.29). This association remained significant after correction for multiple testing. No association was found with cocaine dependence. These data demonstrate the importance of dopamine gene variants in the risk for opioid dependence and highlight a functional polymorphism that warrants further study.
No figures extracted from this document.
← Prev
21–23 of 23
| Name | Type |
|---|---|
| AA | cohort |
| AA cocaine addicted subjects local | cohort |
| AA control individuals local | cohort |
| AA opioid population local | cohort |
| AA population | cohort |
| African American | cohort |
| African American ancestry population local | cohort |
| AKT1 | gene |
| alcohol | phenotype |
| alcohol dependence | phenotype |
| alcohol dependence/abuse local | phenotype |
| Alcohol Use Disorder | phenotype |
| amygdala | anatomy |
| ANKK1 | gene |
| antidepressant therapy local | drug |
| antipsychotics | drug |
| ASW | cohort |
| brain anatomy and function local | phenotype |
| cases | cohort |
| CEU | cohort |
| CEU population | cohort |
| Chinese schizophrenia cohort local | cohort |
| ChronicCocaineAbuse local | phenotype |
| cocaine | phenotype |
| CocaineAbuse local | phenotype |
| CocaineAddiction local | phenotype |
| cocaine population local | cohort |
| cocaine use disorder | phenotype |
| controls | cohort |
| CurrentStudy | cohort |
| D2L local | variant |
| D2 receptor availability local | phenotype |
| D2S local | variant |
| dementia | phenotype |
| depression | phenotype |
| dorsal striatum | anatomy |
| dorsolateral prefrontal cortex | anatomy |
| DRD1 | gene |
| DRD2 | gene |
| DRD2 splice polymorphism local | variant |
| DRD3 | gene |
| drug dependence | phenotype |
| EA | cohort |
| EA control individuals local | cohort |
| EA opioid population local | cohort |
| EA population | cohort |
| EEG slow oscillations local | phenotype |
| epilepsy | phenotype |
| European ancestry | cohort |
| European population | cohort |
| Europeans | cohort |
| HapMap dataset local | cohort |
| healthy controls | cohort |
| heavy drinking | phenotype |
| Heroin dependent subjects local | cohort |
| heroin users | phenotype |
| HIV+ | drug |
| HIV infection | phenotype |
| homicidal ideation local | phenotype |
| Intravenous cocaine users local | cohort |
| Japanese alcoholic cohort local | cohort |
| left basal ganglia local | anatomy |
| lethal cocaine intoxication local | phenotype |
| mania | phenotype |
| morphine | drug |
| motor cortex | anatomy |
| Moyer2011 local | cohort |
| naloxone | drug |
| National Institute of Mental Health Genetics Initiative (NIMH-GI) local | cohort |
| negative decision making local | phenotype |
| nicotine dependence | phenotype |
| NIDA Center for Genetic Studies | cohort |
| NIDA Repository Study 1 local | cohort |
| NIDA Repository Study 13 local | cohort |
| NIDA Repository Study 5 local | cohort |
| NIDA Repository Study 7 local | cohort |
| Olanzapine response local | phenotype |
| opioid | drug |
| Opioid addicted cohort local | cohort |
| opioid dependence | phenotype |
| prefrontal cortex | anatomy |
| psychosis | phenotype |
| psychotropic medication | drug |
| reaction time | phenotype |
| rs1076560 | variant |
| rs2283265 | variant |
| rs28363170 local | variant |
| rs3836790 local | variant |
| Rutgers University Cell & DNA Repository | cohort |
| schizophrenia | phenotype |
| SLC6A3 | gene |
| striatum | anatomy |
| substance use | phenotype |
| suicide | phenotype |
| supplementary motor area | anatomy |
| Taq1A allele | variant |
| Taqman SNP Genotyping Assays | drug |
| thalamus | anatomy |
| University of Pennsylvania | cohort |
| Washington University | cohort |
| working memory | phenotype |
| Yoruban Africans local | cohort |
| YRI population | cohort |
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| The genetic epidemiology of substance use disorder: A review. | 2017 | 28938182 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Convergent Evolution of Two Dopamine Receptor Genes: Repeated Evolution of Exon 6 Skipping in Drd2, and Repeated Deletion of Exon 6 in Drd3. | Peglar MT et al. | — | 2025 | → |
| Interaction Between <i>DRD2</i> rs1076560 Genotype and Stimulant Dependence on Impulsivity and Self-Reported ADHD Traits in Men. | Lachowicz M et al. | — | 2025 | → |
| An emerging multi-omic understanding of the genetics of opioid addiction. | Johnson EO et al. | — | 2024 | → |
| Genetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study. | Panday SK et al. | — | 2024 | → |
| Single Nucleotide Variants (SNVs) of the Mesocorticolimbic System Associated with Cardiovascular Diseases and Type 2 Diabetes: A Systematic Review. | Merzah M et al. | — | 2024 | → |
| Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression. | Holen B et al. | — | 2023 | → |
| Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis. | Blum K et al. | — | 2023 | → |
| The effect of vitamin D on morphine preference in rats: Possible biochemical and DRD2-GDNF signaling. | Saeedfar M et al. | — | 2023 | → |
| The influence of dopamine autoreceptors on temperament and addiction risk. | Zald DH | — | 2023 | → |
| A potential paradigm shift in opioid crisis management: The role of pharmacogenomics. | Eapen-John D et al. | — | 2022 | → |
| Opioid Use Disorder and Alternative mRNA Splicing in Reward Circuitry. | Huggett SB et al. | — | 2022 | → |
| Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS). | Bothos E et al. | — | 2021 | → |
| Medication overuse and drug addiction: a narrative review from addiction perspective. | Takahashi TT et al. | — | 2021 | → |
| Pharmacogenomics of oxycodone: a narrative literature review. | Umukoro NN et al. | — | 2021 | → |
| Clinical and biobehavioral perspectives: Is medication overuse headache a behavior of dependence? | Lau CI et al. | — | 2020 | → |
| Dopamine Receptor DRD2 Gene rs1076560, Personality Traits and Anxiety in the Polysubstance Use Disorder. | Suchanecka A et al. | — | 2020 | → |
| <i>DRD4, DRD2, DAT1,</i> and <i>ANKK1</i> Genes Polymorphisms in Patients with Dual Diagnosis of Polysubstance Addictions. | Masiak J et al. | — | 2020 | → |
| Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. | Abijo T et al. | — | 2020 | → |
| The Streetlight Effect: Reappraising the Study of Addiction in Light of the Findings of Genome-wide Association Studies. | Hall FS et al. | — | 2020 | → |
| Behavioral Changes and Neuronal Damage in Rhesus Monkeys after 10 Weeks of Ketamine Administration Involve Prefrontal Cortex Dopamine D2 Receptor and Dopamine Transporter. | Sun Z et al. | — | 2019 | → |
| Brain default-mode network dysfunction in addiction. | Zhang R et al. | — | 2019 | → |
| Current understanding of the neurobiology of opioid use disorder: An overview. | Moningka H et al. | — | 2019 | → |
| DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum. | Valli M et al. | — | 2019 | → |
| Functional tag SNPs inside the DRD2 gene as a genetic risk factor for major depressive disorder in the Chinese Han population. | He M et al. | — | 2019 | → |
| Genetic variations in the dopamine reward system influence exercise reinforcement and tolerance for exercise intensity. | Flack K et al. | — | 2019 | → |
| Impact of genetic polymorphisms on opioid misuse: a scoping review. | Ahmed S et al. | — | 2019 | → |
| Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis? | Emery MA et al. | — | 2019 | → |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | — | 2019 | → |
| A 35.8 kilobases haplotype spanning ANKK1 and DRD2 is associated with heroin dependence in Han Chinese males. | Zhang J et al. | — | 2018 | → |
| Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. | Randesi M et al. | — | 2018 | → |
| Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. | Schacht JP et al. | — | 2018 | → |
| Neural and psychological characteristics of college students with alcoholic parents differ depending on current alcohol use. | Brown-Rice KA et al. | — | 2018 | → |
| The frequency of <i>DRD2</i> rs1076560 and <i>OPRM1</i> rs1799971 in substance use disorder patients from the United Arab Emirates. | Alblooshi H et al. | — | 2018 | → |
| Blunted Dopamine Transmission in Addiction: Potential Mechanisms and Implications for Behavior. | Trifilieff P et al. | — | 2017 | → |
| Cocaine-induced adaptation of dopamine D2S, but not D2L autoreceptors. | Robinson BG et al. | — | 2017 | → |
| Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117). | Clarke TK et al. | — | 2017 | → |
| GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM<sup>™</sup>): LESSONS LEARNED FROM AMERICA. | Blum K et al. | — | 2017 | → |
| Neurotransmitter receptor genotypes associated with mental and behavioral disorders. | Varoglu E et al. | — | 2017 | → |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | — | 2017 | → |
| Two novel candidate genes identified in adults from the Newfoundland population with addictive tendencies towards food. | Pedram P et al. | — | 2017 | → |
| Endogenous opiates and behavior: 2014. | Bodnar RJ | — | 2016 | → |
| Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families. | Hill SY et al. | — | 2016 | → |
| Relationship among methadone dose, polymorphisms of dopamine D2 receptor and tri-dimensional personality questionnaire in heroin-addicted patients. | Huang MW et al. | — | 2016 | → |
| A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. | Rabin RA et al. | — | 2015 | → |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | — | 2015 | → |
| Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. | Reyes-Gibby CC et al. | — | 2015 | → |
| Genetics and epigenetics of circadian rhythms and their potential roles in neuropsychiatric disorders. | Liu C et al. | — | 2015 | → |
| Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. | Blum K et al. | — | 2015 | → |
| Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. | Blum K et al. | — | 2015 | → |
| Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. | Levran O et al. | — | 2015 | → |
| The significant association of Taq1A genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-analysis of Caucasian populations. | Ma Y et al. | — | 2015 | → |
| Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions. | Ma Y et al. | — | 2015 | → |
| Dopamine and glucose, obesity, and reward deficiency syndrome. | Blum K et al. | — | 2014 | → |
| Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants. | Levran O et al. | — | 2014 | → |
| DRD2/CHRNA5 interaction on prefrontal biology and physiology during working memory. | Di Giorgio A et al. | — | 2014 | → |
| Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. | Blum K et al. | — | 2014 | → |